

Circulation Research

JOURNAL OF THE AMERICAN HEART ASSOCIATION

American Heart
Association® 
Learn and Live™

Adenosine Receptors and Angiogenesis

John A. Auchampach

Circ. Res. 2007;101;1075-1077

DOI: 10.1161/CIRCRESAHA.107.165761

Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75214

Copyright © 2007 American Heart Association. All rights reserved. Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://circres.ahajournals.org/cgi/content/full/101/11/1075>

Subscriptions: Information about subscribing to Circulation Research is online at
<http://circres.ahajournals.org/subscriptions/>

Permissions: Permissions & Rights Desk, Lippincott Williams & Wilkins, a division of Wolters Kluwer Health, 351 West Camden Street, Baltimore, MD 21202-2436. Phone: 410-528-4050. Fax: 410-528-8550. E-mail:
journalpermissions@lww.com

Reprints: Information about reprints can be found online at
<http://www.lww.com/reprints>

Adenosine Receptors and Angiogenesis

John A. Auchampach

As originally hypothesized by Berne,¹ adenosine is formed in the heart during hypoxia or ischemia and serves as a negative feedback signal to maintain oxygen delivery within a normal physiological range. Adenosine is formed by the metabolism of ATP and transported into the extracellular space by various nucleoside transport proteins.² In a more localized manner that provides the opportunity for coordinated signaling with the diverse P₂ purinoreceptor family that recognizes ATP and ADP, adenosine is also formed from the extracellular metabolism of adenine nucleotides released from stored granules (sympathetic nerves, platelets, mast cells) or through hemichannels (neutrophils, endothelial cells, epithelial cells) by ecto-apyrases and ecto-nucleotidases.^{3–5} Adenosine signals through activation of widely distributed cell surface G protein–coupled receptors, of which 4 different subtypes have been identified designated A₁, A_{2A}, A_{2B}, and A₃.⁶ By activating A_{2A} receptors that are abundantly expressed in coronary vascular smooth muscle, adenosine generated under hypoxic conditions produces potent vasodilation thereby increasing nutrient and oxygen delivery.

Although less appreciated, adenosine also serves to maintain tissue oxygenation in response to chronic ischemic/hypoxic stress by increasing the formation of new blood vessels; that is, by stimulating angiogenesis.^{7,8} Using adenosine receptor agonists or modulators of adenosine metabolism, an important role for adenosine has been established in *in vivo* models of angiogenesis.^{7,8} In cell culture systems, adenosine stimulates endothelial cell migration, proliferation, and tube formation,^{7–11} actions required for the formation of new capillary networks. This action occurs at concentrations of adenosine that are reached in hypoxic tissues. Adair⁷ recently estimated that adenosine can contribute up to 50% to 70% of the angiogenic response in some cases.

Adenosine has direct mitogenic effects on vascular cells that may contribute to angiogenesis. However, the main proangiogenic actions of adenosine have been attributed to its ability to regulate the production of pro- and antiangiogenic substances from vascular cells and immune cells within the microenvironment of hypoxic tissues. Adeno-

sine stimulates the release of interleukin-8 (IL-8), basic fibroblast growth factor (bFGF), and vascular endothelial growth factor (VEGF) from endothelial cells via A_{2B} receptors that are dually coupled to G_s and G_q proteins while inhibiting production of the antiangiogenic factor thrombospondin-1, seemingly by the G_s protein–coupled A_{2A} receptor.^{9,10} Adenosine also stimulates the production of VEGF, IL-8, and angiopoietin-1 from mast cells via A_{2B} and A₃ receptors.¹¹ A unique mechanism has been identified by Lebovich and colleagues¹² in which adenosine activation of the A_{2A} receptor converts macrophages from a proinflammatory phenotype that generates large amounts of tumor necrosis factor- α and IL-6 to a proangiogenic phenotype that predominantly secretes VEGF. This particular mechanism is likely important in promoting tissue repair following wounding or microbial infection.

In this issue of *Circulation Research*, Clark and colleagues¹³ demonstrate for the first time that the A₁ adenosine receptor also participates in the angiogenic actions of adenosine. The A₁ receptor is a G_i protein–coupled receptor that is well-known in the cardiovascular system to mediate the negative chronotropic, negative dromotropic, and antiadrenergic actions of adenosine responsible for reducing oxygen demand during metabolic stress.¹⁴ Using the chick chorioallantoic membrane model, Clark et al¹³ demonstrated that the selective A₁ receptor agonist N⁶-cyclopentyladenosine (CPA) increased membrane vessel number by 40%. This effect produced by CPA was inhibited by the highly selective A₁ receptor antagonist WRC-0571 confirming involvement of the A₁ receptor. The authors¹³ need to be commended for devoting substantial effort in cloning and pharmacologically characterizing 3 of the 4 chick adenosine receptors to verify the selectivity of the pharmacological agents used in their study, as the binding affinities of adenosine receptor ligands are well known to differ markedly among species.^{15,16} A₁ adenosine receptor expression has been reported previously in the vasculature,^{17,18} suggesting that CPA may function through a direct mitogenic action. However, CPA did not promote capillary formation in an aortic ring model of angiogenesis, leading the authors to conclude that the actions of CPA are indirect involving nonvascular cells. Among cells known to be involved in the angiogenic response, monocytes express A₁ receptors.¹⁹ Acting on this lead, the authors showed that: (1) CPA stimulated VEGF release from isolated peripheral human monocytes through an A₁ receptor-mediated mechanism, and (2) conditioned media from CPA-treated monocytes promoted vessel growth in the aortic ring model, which was blocked by the addition of an anti-VEGF antibody. Collectively, these results suggest that A₁ receptor-mediated angiogenesis may involve the release of VEGF from monocytes. This study is

The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.

From the Department of Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee.

Correspondence to John A. Auchampach, PhD, Department of Pharmacology & Toxicology, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226. E-mail jauchamp@mcw.edu

(*Circ Res.* 2007;101:1075–1077.)

© 2007 American Heart Association, Inc.

Circulation Research is available at <http://circres.ahajournals.org>
DOI: 10.1161/CIRCRESAHA.107.165761

important to our understanding of mechanisms of angiogenesis and the identification of the A₁ receptor as a new therapeutic target. This is also the first study to demonstrate that A₁ receptor activation promotes the release of a proangiogenic substance from an immune cell population. Previously, the only known function of the A₁ receptor in the immune system is to promote migration of neutrophils and dendritic cells.²⁰

Clark and colleagues¹³ are careful to emphasize that the 2 major findings in their study may not be interrelated. That is, it is possible that A₁ receptor-mediated angiogenesis in the chick chorioallantoic membrane model may involve other mechanisms that do not involve the release of VEGF from monocytes. Considering that A₁ receptors facilitate migration of some immune cells,⁸ one interesting possibility is that CPA increased vasculogenesis. After wounding, adenosine has been implicated in mediating recruitment of endothelial progenitor cells to sites of neovascular formation.²¹ The authors¹³ also note that the importance of the A₁ receptor in angiogenesis needs to be demonstrated in mammalian models. This work will be facilitated by the availability of mice with global deletion of adenosine receptor genes as well as mice with tissue-specific deletion of adenosine receptors. If confirmed, the exciting possibility will exist that pharmacological therapies targeting A₁ receptor function may provide a basis for treating coronary artery disease, cancer, or other diseases in which the underlying basis is exaggerated or limited angiogenesis. Of note, the clinical use of direct A₁ agonists as proangiogenic agents would face several obstacles, such as the potential to produce undesirable cardiovascular effects including bradycardia, atrioventricular block, and hypotension. Small molecule allosteric enhancers of the A₁ receptor, which do not directly activate the receptor but instead enhance the actions of endogenous adenosine by increasing coupling efficiency to G proteins, may prove to be more useful.^{22,23} These agents could theoretically lead to angiogenesis in those tissue areas where hypoxia is greatest without affecting systemic hemodynamic parameters. Cardiovascular side-effects may also be minimized by using partial A₁ receptor agonists that elicit submaximal responses even when administered at high doses.^{24,25} The use of A₁ receptor antagonists to reduce angiogenesis may be less problematic. Afzal and colleagues²⁶ recently reported that intraocular injection of a ribozyme specific for the A_{2B} receptor reduced preretinal neovascularization in a neonatal mouse model of oxygen-induced retinopathy, highlighting the feasibility of using genetic approaches to modulate adenosine-mediated angiogenesis.

In summary, Clark et al¹³ have made the novel discovery that A₁ adenosine receptor activation can stimulate angiogenesis in an established experimental model. Combined with previous work conducted by others, it now appears that all 4 adenosine receptor subtypes participate in mediating the angiogenic actions of adenosine, working in a coordinated fashion involving indirect and direct actions on endothelial cells, smooth muscle cells, fibroblasts, and resident immune cells including monocytes, macrophages, and mast cells (see Figure 7 in Clark et al¹³). The relative

importance of each adenosine receptor subtype awaits further investigation.

Sources of Funding

The author is supported by NIH R01 grants HL60051 and HL077707.

Disclosures

None.

References

1. Feigl EO. Berne's adenosine hypothesis of coronary blood flow control. *Am J Physiol*. 2004;287:H1891–H1894.
2. Thorn JA, Jarvis SM. Adenosine transporters. *Gen Pharmacol*. 1996;27:613–620.
3. Burnstock G. Purinergic signalling—an overview. *Novartis Foundation Symposium*. 2006;276:26–48.
4. Eltzschig HK, Eckle T, Mager A, Kuper N, Karcher C, Weissmuller T, Boengler K, Schulz R, Robson SC, Colgan SP. ATP release from activated neutrophils occurs via connexin 43 and modulates adenosine-dependent endothelial cell function. *Circ Res*. 2006;99:1100–1108.
5. Eltzschig HK, Weissmuller T, Mager A, Eckle T. Nucleotide metabolism and cell-cell interactions. *Meth Mol Biol*. 2006;341:73–87.
6. Fredholm BB, Arslan G, Halldner L, Kull B, Schulte G, Wasserman W. Structure and function of adenosine receptors and their genes. *Naunyn-Schmied Arch Pharmacol*. 2000;362:364–374.
7. Adair TH. Growth regulation of the vascular system: an emerging role for adenosine. *Am J Physiol Regul Integr Comp Physiol*. 2005;289:R283–R296.
8. Cronstein BN. Adenosine receptors and wound healing. *Sci World J*. 2004;4:1–8.
9. Desai A, Victor-Vega C, Gadangi S, Montesinos MC, Chu CC, Cronstein BN. Adenosine A_{2A} receptor stimulation increases angiogenesis by down-regulating production of the antiangiogenic matrix protein thrombospondin 1. *Mol Pharmacol*. 2005;67:1406–1413.
10. Feoktistov I, Goldstein AE, Ryzhov S, Zeng D, Belardinelli L, Voynoyasenetskaya T, Biaggioni I. Differential expression of adenosine receptors in human endothelial cells: role of A_{2B} receptors in angiogenic factor regulation. *Circ Res*. 2002;90:531–538.
11. Feoktistov I, Ryzhov S, Goldstein AE, Biaggioni I. Mast cell-mediated stimulation of angiogenesis: cooperative interaction between A_{2B} and A₃ adenosine receptors. *Circ Res*. 2003;92:485–492.
12. Olah ME, Caldwell CC. Adenosine receptors and mammalian toll-like receptors: synergism in macrophages. *Mol Inter*. 2003;3:370–374.
13. Clark AN, Youkey R, Liu X, Jia L, Blatt R, Day YJ, Sullivan GW, Linden J, Tucker AL. A₁ Adenosine Receptor Activation Promotes Angiogenesis and Release of VEGF From Monocytes. *Circ Res*. 2007;101:1130–1138.
14. Shryock JC, Belardinelli L. Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. *Am J Cardiol*. 1997;79:2–10.
15. Linden J. Cloned adenosine A₃ receptors: pharmacological properties, species differences and receptor functions. *Trends Pharmacol Sci*. 1994;15:298–306.
16. Tucker AL, Robeva AS, Taylor HE, Holeton D, Bockner M, Lynch KR, Linden J. A₁ adenosine receptors. Two amino acids are responsible for species differences in ligand recognition. *J Biol Chem*. 1994;269:27900–27906.
17. Stanimirovic DB, Bertrand N, Merkel N, Bembry J, Spatz M. Interaction between histamine and adenosine in human cerebrovascular endothelial cells: modulation of second messengers. *Metab Brain Dis*. 1994;9:275–289.
18. Wilson CN, Batra VK. Lipopolysaccharide binds to and activates A₁ adenosine receptors on human pulmonary artery endothelial cells. *J Endotox Res*. 2002;8:263–271.

19. Thiele A, Kronstein R, Wetzel A, Gerth A, Nieber K, Hauschildt S. Regulation of adenosine receptor subtypes during cultivation of human monocytes: role of receptors in preventing lipopolysaccharide-triggered respiratory burst. *Infect Immun*. 2004;72:1349–1357.
20. Hasko G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. *Trend Immunol*. 2004;25:33–39.
21. Montesinos MC, Shaw JP, Yee H, Shamamian P, Cronstein BN. Adenosine A_{2A} receptor activation promotes wound neovascularization by stimulating angiogenesis and vasculogenesis. *Am J Pathol*. 2004;164:1887–1892.
22. Chordia MD, Zigler M, Murphree LJ, Figler H, Macdonald TL, Olsson RA, Linden J. 6-aryl-8H-indeno[1,2-d]thiazol-2-ylamines: A₁ adenosine receptor agonist allosteric enhancers having improved potency. *J Med Chem*. 2005;48:5131–5139.
23. Figler H, Olsson RA, Linden J. Allosteric enhancers of A₁ adenosine receptors increase receptor-G protein coupling and counteract Guanine nucleotide effects on agonist binding. *Mol Pharmacol*. 2003;64:1557–1564.
24. Dhalla AK, Wong MY, Voshol PJ, Belardinelli L, Reaven GM. A₁ adenosine receptor partial agonist lowers plasma FFA and improves insulin resistance induced by high-fat diet in rodents. *Am J Physiol Endocrinol Metab*. 2007;292:E1358–E1363.
25. Zablocki JA, Wu L, Shryock J, Belardinelli L. Partial A₁ adenosine receptor agonists from a molecular perspective and their potential use as chronic ventricular rate control agents during atrial fibrillation (AF). *Curr Top Medl Chem*. 2004;4:839–854.
26. Afzal A, Shaw LC, Caballero S, Spoerri PE, Lewin AS, Zeng D, Belardinelli L, Grant MB. Reduction in preretinal neovascularization by ribozymes that cleave the A_{2B} adenosine receptor mRNA. *Circ Res*. 2003;93:500–506.

KEY WORDS: adenosine ■ angiogenesis ■ receptors ■ ischemia ■ heart